Lower Blenrep Dose More Feasible With Revlimid in Myeloma, Early Trial Suggests
A dose-finding study presented at the recent American Society of Hematology annual meeting showed deep and durable responses with belantamab mafodotin (Blenrep) plus lenalidomide (Revlimid) and dexamethasone in relapsed or refractory multiple myeloma, with lower dosing of the B-cell maturation antigen (BCMA) proving more tolerable and feasible. In this MedPage Today video, Rakesh Popat, BSc, […]